Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ONIPF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
h3G10.2.37-h3G10.2.72 vc0101
|
|||||
| Synonyms |
h3G10.2.37 h3G10.2.72 vc0101
Click to Show/Hide
|
|||||
| Organization |
Pfizer Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 4 Indication(s)
Adult T acute lymphoblastic leukemia [ICD11:2A90]
Investigative
Burkitt lymphoma [ICD11:2A85]
Investigative
Mature T-cell lymphoma [ICD11:2A90] [ICD11:2A90]
Investigative
Plasma cell myeloma [ICD11: 2A83]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
h3G10.2.37-h3G10.2.72
|
Antibody Info | ||||
| Antigen Name |
C-X-C chemokine receptor type 4 (CXCR4)
|
Antigen Info | ||||
| Payload Name |
Auristatin 0101
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.